Ligeti László, Szenczi Orsolya, Prestia Christina M, Szabó Csaba, Horváth Katalin, Marcsek Zoltán L, van Stiphout Ruud G P M, van Riel Natal A W, Op den Buijs Jorn, Van der Vusse Ger J, Ivanics Tamás
Institute of Human Physiology and Clinical Experimental Research, Semmelweis University, Budapest, Hungary.
Int J Mol Med. 2006 Jun;17(6):1035-43.
The main objective of the present study was to determine alterations of calcium handling in the diabetic rat heart during the transition from adaptive to maladaptive phase of cardiomyopathy. By inhibiting the nuclear enzyme poly(ADP-ribose) polymerase (PARP), we also investigated the possible role of this enzyme in the sequence of pathological events. Six weeks after induction of type I diabetes by injection of streptozotocin in rats, the hearts were perfused according to Langendorff. Intracellular-free calcium (Ca(2+)(i)) levels were measured by surface fluorometry using Indo-1 AM. Cyclic changes in Ca(2+)(i) concentrations and hemodynamic parameters were measured simultaneously. The hearts were challenged by infusion of isoproterenol. Six weeks of diabetes resulted in reduced inotropy and lusitropy. The diabetic hearts (DM) expressed a significantly elevated end-diastolic Ca(2+)(i) level (control, 111-/+20 vs DM, 221-/+35 nM). The maximal transport capacity of SERCA2a and conductance of RyR2 were reduced. These changes were not accompanied by major alterations in the tissue content of SERCA2a, RyR2, phospholamban and Na(+)/Ca(2+) exchanger. In response to beta-adrenergic activation, SERCA2a transport capacity and RyR2 conductance were stunted in the DM hearts. Inhibition of PARP induced minor changes in the mechanical function and calcium handling of the DM hearts. In conclusion, the observed changes in contractility and in Ca(2+)(i) handling are most likely attributable to functional disturbances of SERCA2a and RyR2 in this transitional phase of diabetes. At this stage of diabetes, PARP does not appear to play a significant pathogenetic role in the alterations in contractile function and calcium handling.
本研究的主要目的是确定糖尿病大鼠心脏在心肌病从适应性阶段向适应不良阶段转变过程中钙处理的变化。通过抑制核酶聚(ADP - 核糖)聚合酶(PARP),我们还研究了该酶在病理事件序列中的可能作用。通过给大鼠注射链脲佐菌素诱导I型糖尿病六周后,根据Langendorff法对心脏进行灌注。使用Indo - 1 AM通过表面荧光法测量细胞内游离钙(Ca(2+)(i))水平。同时测量Ca(2+)(i)浓度和血流动力学参数的周期性变化。通过输注异丙肾上腺素对心脏进行刺激。糖尿病六周导致心肌收缩力和舒张功能降低。糖尿病心脏(DM)的舒张末期Ca(2+)(i)水平显著升高(对照组,111±20 vs DM,221±35 nM)。SERCA2a的最大转运能力和RyR2的电导降低。这些变化并未伴随SERCA2a、RyR2、受磷蛋白和Na(+)/Ca(2+)交换器组织含量的重大改变。响应β - 肾上腺素能激活,DM心脏中SERCA2a的转运能力和RyR2的电导受到阻碍。抑制PARP在DM心脏的机械功能和钙处理方面引起轻微变化。总之,在糖尿病的这个过渡阶段,观察到的收缩性和Ca(2+)(i)处理的变化很可能归因于SERCA2a和RyR2的功能障碍。在糖尿病的这个阶段,PARP似乎在收缩功能和钙处理的改变中不发挥重要的致病作用。